What it is
Thymulin (FTS-Zn) is a zinc-binding nonapeptide produced by thymic epithelial cells. It supports T-cell differentiation and effective immune responses, with anti-inflammatory and immunomodulatory effects relevant to autoimmunity, allergic disease, and pain modulation.
Mechanism of action
Biological activity requires zinc — the Zn2+ form binds T-cell membrane receptors and modulates T-cell maturation, NK activity, and cytokine balance. Animal models support roles in restraining Th17-driven autoimmune inflammation.
Half-life: Short — typical thymic peptide kinetics; therapeutic regimens deliver repeated doses.
Evidence summary
Earlier clinical data in rheumatoid arthritis (1984, 1987) showed clinical and immune improvements. Modern preclinical work demonstrates benefit in allergic asthma, experimental autoimmune encephalomyelitis, and inflammatory pain pathways via spinal signalling.
Pantheon dosing guide
- Application
- Subcutaneous injection.
- BAC Water
- 2 ml
- Dose
- 10 units (500 mcg) to 20 units (1000 mcg).
- Frequency & Cycle Length
- Daily for up to 20 days.
- Timing
- Take in the morning on an empty stomach, at least 30 minutes before eating.
- Key Benefits
- Strengthens immune system. Reduces inflammation, Supports hormonal balance. Helps regulate autoimmune activity. Helps your body heal and repair tissues faster.
Additional research protocol context
The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.
- 100–500 mcg subcutaneous, 2–3× weekly
- 8-week cycles for immune modulation research
- Co-supplementation with zinc commonly cited
Side effects & safety
- Generally well-tolerated in published trials
- Mild injection-site reactions
- Long-term human safety data is limited
Cited studies
- (1984). Thymuline (FTS) in rheumatoid arthritis. Arthritis and Rheumatism.Read source ↗
- (1987). An open trial of thymulin (FTS-Zn) in rheumatoid arthritis patients: sequential clinical and immunological follow-up. Clinical and Experimental Rheumatology.Read source ↗
- (2013). Thymic peptides restrain the inflammatory response in mice with experimental autoimmune encephalomyelitis. Immunobiology.Read source ↗
- (2019). Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against the Relapsing-Remitting Form of Experimental Autoimmune Encephalomyelitis in Mice. International Journal of Molecular Sciences (MDPI).Read source ↗
- (2019). Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways. International Immunopharmacology.Read source ↗
- (2020). Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma. Science Advances.Read source ↗
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.